Tools / Drug approvals and letters / Drugs Carbidopa; Levodopa Treats Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism. Sold as Sinemet, Sinemet Cr, Rytary, Duopa, Dhivy and 1 more. Every FDA application for this active ingredient: 6 branded and 37 generic.
As of Nov 15, 2026, FDA lists 43 applications for Carbidopa; Levodopa (sold as Sinemet, Sinemet Cr, Rytary and others), first approved May 2, 1975, with 0 new uses approved and 1 published complete response letter.
First approved : May 2, 1975 Applications : 43 New uses approved : 0 Complete response letters : 1 Medicare spending, 2025 : $480M
Medicare Spending CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name Product Part Spending, 2025 Change Beneficiaries Rytary Part D $258M -5% 33,757 Carbidopa-Levodopa Part D $90.0M -1% 589,213 Crexont Part D $55.1M +2111% 15,860 Duopa Part B $43.5M -18% 562 Carbidopa-Levodopa ER Part D $29.4M -2% 144,305 Duopa Part D $2.9M +2% 47 Dhivy Part D $985K +1% 420 Sinemet Part D $320K +4% 235
What Pharmacies Pay Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change CARBIDOPA-LEVODOPA 10-100 TAB: $0.074 per unit Generic · -12% in a year CARBIDOPA-LEVODOPA 25-100 TAB: $0.074 per unit Generic · -8% in a year CARBIDOPA-LEVODOPA 25-250 TAB: $0.125 per unit Generic · 0% in a year SINEMET 25-100 MG TABLET: $1.42 per unit Brand · +5% in a year RYTARY ER 23.75 MG-95 MG CAP: $3.98 per unit Brand · 0% in a year RYTARY ER 36.25 MG-145 MG CAP: $3.97 per unit Brand · 0% in a year RYTARY ER 48.75 MG-195 MG CAP: $3.98 per unit Brand · +0% in a year RYTARY ER 61.25 MG-245 MG CAP: $5.00 per unit Brand · 0% in a year DHIVY 25-100 MG TABLET: $3.61 per unit Brand · +5% in a year CREXONT ER 35 MG-140 MG CAP: $4.59 per unit Brand · +6% in a year CREXONT ER 52.5 MG-210 MG CAP: $4.58 per unit Brand · +5% in a year CREXONT ER 70 MG-280 MG CAP: $4.58 per unit Brand · +5% in a year FDA Drug Safety Communications One communication since 2020 that name this drug; see all communications Clinical Trials 27 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients PARKINSON DISEASE (Disorder) · Navamedic AB Phase 4 Recruiting Sep 24, 2026 Comparison of Benzhexol and Procyclidine for Tremor in Tremor-Predominant Parkinson's Disease Parkinson Disease (PD) · safia bano Not applicable Recruiting Sep 9, 2026 Metformin in Parkinson's Disease: Safety and Efficacy Parkinsons Disease (PD) · Jinnah Medical & Dental College Phase 4 Not yet recruiting Sep 8, 2026 Brain Dopamine Biomarker Parkinson Disease, Healthy Adult Participants · University of South Florida — Not yet recruiting Aug 6, 2026 Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB1 Gene) CTNNB1, L-DOPA · University Hospital, Montpellier Not applicable Recruiting May 29, 2026 Etoricoxib in Patients With Parkinsonian Disease Parkinson Disease · Ihab Elsayed Hassan Phase 2 Recruiting Jan 27, 2026 Celecoxib in Parkinson Disease as Adjuvant Therapy Parkinson Disease · Tanta University Phase 1 / Phase 2 Recruiting Nov 24, 2025 Metformin in Parkinson Disease Parkinson Disease · Tanta University Phase 2 / Phase 3 Recruiting Nov 17, 2025
Applications NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing May 2, 1975 Sinemet NDA 17555 · New molecular entity, new combination Organon59 Marketed May 30, 1991 Sinemet Cr NDA 19856 · New dosage form Organon LLC23 Discontinued Aug 28, 1992 Carbidopa And Levodopa ANDA 73618 Dr Reddys Labs SA14 Marketed Aug 28, 1992 Carbidopa And Levodopa ANDA 73589 Dr Reddys Labs SA14 Marketed Aug 28, 1992 Carbidopa And Levodopa ANDA 73607 Dr Reddys Labs SA15 Marketed Sep 3, 1993 Carbidopa And Levodopa ANDA 74260 Actavis Elizabeth16 Marketed Mar 25, 1994 Carbidopa And Levodopa ANDA 74080 Scs0 Discontinued Jun 29, 1995 Carbidopa And Levodopa ANDA 73587 Ani Pharms5 Discontinued Jun 29, 1995 Carbidopa And Levodopa ANDA 73586 Idt Australia Ltd5 Discontinued Sep 30, 1999 Carbidopa And Levodopa ANDA 75091 Mylan11 Marketed May 14, 2004 Carbidopa And Levodopa ANDA 76521 Impax Labs3 Marketed Jun 16, 2004 Carbidopa And Levodopa ANDA 76212 Apotex3 Discontinued Jun 24, 2004 Carbidopa And Levodopa ANDA 76663 Kv Pharm0 Discontinued Aug 27, 2004 Parcopa ANDA 76699 Ucb Inc1 Discontinued Jun 10, 2005 Carbilev ANDA 76643 Ranbaxy0 Discontinued Aug 23, 2007 Carbidopa And Levodopa ANDA 77828 Sun Pharm Inds2 Discontinued Jun 2, 2008 Carbidopa And Levodopa ANDA 77120 Apotex Inc4 Discontinued Sep 18, 2008 Carbidopa And Levodopa ANDA 78893 Rising1 Marketed Oct 28, 2008 Carbidopa And Levodopa ANDA 78536 Sun Pharm Inds6 Marketed Jul 31, 2009 Carbidopa And Levodopa ANDA 78690 Sun Pharm0 Marketed Sep 28, 2009 Carbidopa And Levodopa ANDA 90324 Pharmobedient3 Marketed Jun 8, 2010 Carbidopa And Levodopa ANDA 90631 Impax Labs0 Discontinued Feb 8, 2013 Carbidopa And Levodopa ANDA 202323 Accord Hlthcare3 Marketed Jan 7, 2015 Rytary NDA 203312 · New formulation or manufacturer Impax7 Marketed Jan 9, 2015 Duopa NDA 203952 · New dosage form Abbvie7 Marketed Jun 5, 2019 Carbidopa And Levodopa ANDA 210341 Alembic1 Marketed May 7, 2021 Carbidopa And Levodopa ANDA 214092 Sciegen Pharms1 Marketed Oct 5, 2021 Carbidopa And Levodopa ANDA 214091 Sciegen Pharms1 Marketed Nov 12, 2021 Dhivy NDA 214869 · New formulation or manufacturer Avion Pharms3 Marketed Sep 21, 2022 Carbidopa And Levodopa ANDA 216505 Rubicon Research1 Marketed Nov 28, 2022 Carbidopa And Levodopa ANDA 216537 Aurobindo Pharma Ltd1 Marketed Apr 4, 2023 Carbidopa And Levodopa ANDA 215999 Zydus Pharms0 Discontinued Jun 4, 2024 Carbidopa And Levodopa ANDA 217482 Rubicon Research1 Marketed Aug 7, 2024 Crexont NDA 217186 · New dosage form Impax2 Marketed Jan 14, 2025 Carbidopa And Levodopa ANDA 218939 Ascent Pharms Inc0 Marketed Nov 2, 2026 Carbidopa And Levodopa ANDA 208522 Actavis Labs Fl0 Marketed — Carbidopa And Levodopa ANDA 73383 Watson Labs0 Discontinued — Carbidopa And Levodopa ANDA 73381 Watson Labs0 Discontinued — Carbidopa And Levodopa ANDA 73382 Watson Labs0 Discontinued — Carbidopa; Levodopa ANDA 208895 Sandoz Inc0 Discontinued — Carbidopa And Levodopa ANDA 219231 Dr Reddys Labs Ltd0 Discontinued — Carbidopa And Levodopa ANDA 219989 Sandoz Inc0 Discontinued — Carbidopa And Levodopa ANDA 220119 Biocon Pharma Limited0 Discontinued
Complete Response Letters FDA's published letters for these applications Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA